Results 41 to 50 of about 53,933 (241)

Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection. [PDF]

open access: yes, 2016
Primary biliary cholangitis (PBC), previously known as primary biliary "cirrhosis", is a rare autoimmune liver disease characterized by the hallmark autoantibodies to mitochondrial antigens and immune-mediated destruction of small bile duct epithelial ...
Bowlus, Christopher L
core   +3 more sources

The Novel Compounds That Activate Farnesoid X Receptor: the Diversity of Their Effects on Gene Expression

open access: yesJournal of Pharmacological Sciences, 2008
Farnesoid X receptor (FXR) controls the expression of critical genes in bile acid and cholesterol homeostasis. To study FXR and to develop a regulator of cholesterol, some nonsteroidal and steroidal ligands have been found in addition to endogenous ...
Takuo Suzuki   +12 more
doaj   +1 more source

Mechanisms underlying bone loss associated with gut inflammation [PDF]

open access: yes, 2019
Patients with gastrointestinal diseases frequently suffer from skeletal abnormality, characterized by reduced bone mineral density, increased fracture risk, and/or joint inflammation.
Abu-Amer, Yousef, Arra, Manoj, Ke, Ke
core   +2 more sources

Nonalcoholic steatohepatitis pharmacotherapy and predictors of response: dual role of aminotransferases as biosensors of metabolism and biomarkers of histological improvement [PDF]

open access: yes, 2019
Nonalcoholic steatohepatitis (NASH)—the severe histological form of nonalcoholic fatty liver disease (NAFLD)—is regarded as a major health problem worldwide (1,2).
Pirola, Carlos José   +1 more
core   +1 more source

Molecular tuning of farnesoid X receptor partial agonism

open access: yesNature Communications, 2019
The ligand-activated transcription factor farnesoid X receptor (FXR) acts as a cellular sensor for bile acids and is of interest as a drug target. Here the authors employ X-ray crystallography and NMR to characterize the molecular determinants of FXR ...
Daniel Merk   +14 more
doaj   +1 more source

BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis

open access: yesJournal of Lipid Research, 2002
During the last three years there have been a plethora of publications on the liver X-activated receptors (LXRα, NR1H3, and LXRβ, NR1H2), the farnesoid X-activated receptor (FXR, NR1H4), and the pregnane X receptor (PXR, NR1I2) and the role these nuclear
Peter A. Edwards   +2 more
doaj   +1 more source

Farnesoid X receptor and fibroblast growth factor 15/19 as pharmacological targets

open access: yesLiver Research, 2021
The farnesoid X receptor (FXR) is a nuclear receptor and transcriptional regulator activated by bile acids or synthetic FXR agonists. FXR is expressed highly in the liver and intestine where modulation of FXR critically regulates the expression of genes ...
S. Maliha, G. Guo
semanticscholar   +1 more source

The role of lipid and lipoprotein metabolism in non-alcoholic fatty liver disease [PDF]

open access: yes, 2017
Due to the epidemic of obesity across the world, nonalcoholic fatty liver disease (NAFLD) has become one of the most prevalent chronic liver disorders in children and adolescents.
Anania, Caterina   +4 more
core   +2 more sources

Arbutin Alleviates the Liver Injury of α-Naphthylisothiocyanate-induced Cholestasis Through Farnesoid X Receptor Activation

open access: yesFrontiers in Cell and Developmental Biology, 2021
Cholestasis is a kind of stressful syndrome along with liver toxicity, which has been demonstrated to be related to fibrosis, cirrhosis, even cholangiocellular or hepatocellular carcinomas.
Pei-Shan Wu   +6 more
semanticscholar   +1 more source

Regulation of inflammatory and lipid metabolism genes by eicosapentaenoic acid-rich oil[S]

open access: yesJournal of Lipid Research, 2012
Omega-3-PUFAs, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), are associated with prevention of various aspects of metabolic syndrome.
Peter J. Gillies   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy